Inclusion Criteria:

          -  At least 18 years of age

          -  Histologically confirmed, measurable or non-measurable, recurrent or persistent,
             platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
             By standard Gynecologic Oncology Group (GOG) criteria, platinum-resistant disease is
             defined by a disease-free interval of less than 6 months following treatment with a
             platinum-based regimen, or the progression of disease during platinum-based therapy.

          -  At least one prior regimen of chemotherapy, with no maximum number of chemotherapy
             cycles

          -  A serum creatinine ≤ 1.5 mg% obtained ≤ 2 weeks prior to entry

          -  Adequate hematologic reserve obtained ≤ 2 weeks prior to entry: leukocytes ≥ 3,000
             mm^3; absolute neutrophil count ≥ 1500 mm^3; platelets ≥ 100,000 mm^3

          -  Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine
             transaminase (ALT) ≤ 3x upper limit of normal within institutional limits; bilirubin ≤
             1.5 mg/dl

          -  Gynecologic Oncology Group (GOG) Performance Status of 0, 1, or 2

          -  Life expectancy of at least 90 days

          -  The patient should be off chemotherapy, biologic therapy and radiation for 28 days.

          -  Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity
             Criteria (CTC) version 4

        Exclusion Criteria:

          -  Prior TCN-PM therapy

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to TCN-PM

          -  Patients must be disease-free of prior invasive malignancies for >2 years with the
             exception of basal cell or squamous cell carcinoma of the skin.

          -  Inability to give informed consent

          -  Pregnancy

          -  Corrected QT interval (QTc) prolongation > 450 milliseconds (msec)